Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas
dc.contributor.author | Shulkin, Barry L. | en_US |
dc.contributor.author | Ilias, Ioannis | en_US |
dc.contributor.author | Sisson, James C. | en_US |
dc.contributor.author | Pacak, Karel | en_US |
dc.date.accessioned | 2010-06-01T21:50:36Z | |
dc.date.available | 2010-06-01T21:50:36Z | |
dc.date.issued | 2006-08 | en_US |
dc.identifier.citation | SHULKIN, BARRY L . ; ILIAS, IOANNIS; SISSON, JAMES C . ; PACAK, KAREL (2006). "Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas." Annals of the New York Academy of Sciences 1073(1 Pheochromocytoma: First International Symposium ): 374-382. <http://hdl.handle.net/2027.42/74881> | en_US |
dc.identifier.issn | 0077-8923 | en_US |
dc.identifier.issn | 1749-6632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74881 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17102106&dopt=citation | en_US |
dc.description.abstract | Most pheochromocytomas/paragangliomas should be evaluated with anatomical imaging (computed tomography or magnetic resonance imaging) followed by functional imaging (nuclear medicine modalities). Functional imaging assures that the tumor is indeed a pheochromocytoma/paraganglioma and enables more thorough localization, especially detecting as many lesions as possible (in particular for metastatic disease). Functional imaging for pheochromocytomas/paragangliomas, can use radiolabled ligands specific for pathways of synthesis, metabolism, and inactivation of catecholamines or nonspecific ligands. In an overview of the available nuclear medicine modalities, we summarize the accumulated experience and recommend when functional imaging should be applied to patients with pheochromocytoma/paraganglioma. | en_US |
dc.format.extent | 190906 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | 2006 New York Academy of Sciences | en_US |
dc.subject.other | Nuclear Medicine Methods | en_US |
dc.subject.other | Radionuclide Imaging | en_US |
dc.subject.other | Positron Emission Tomography | en_US |
dc.subject.other | Pheochromocytoma Diagnosis | en_US |
dc.title | Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Science (General) | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical Center, 1500 East Medical Center Drive, UH B1G 505D, Ann Arbor, Michigan 48109-0028, USA | en_US |
dc.contributor.affiliationother | Division of Nuclear Medicine, Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA | en_US |
dc.contributor.affiliationother | Department of Pharmacology, Medical School, University of Patras, Rion-GR-26504, Greece | en_US |
dc.contributor.affiliationother | Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1109, USA | en_US |
dc.identifier.pmid | 17102106 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74881/1/annals.1353.041.pdf | |
dc.identifier.doi | 10.1196/annals.1353.041 | en_US |
dc.identifier.source | Annals of the New York Academy of Sciences | en_US |
dc.identifier.citedreference | Neumann, H.P. et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459 – 1466. | en_US |
dc.identifier.citedreference | Mundschenk, J. et al. 1998. Malignant pheochromocytoma. Exp. Clin. Endocrinol. Diabetes 106: 373 – 376. | en_US |
dc.identifier.citedreference | Averbuch, S.D. et al. 1988. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann. Intern. Med. 109: 267 – 273. | en_US |
dc.identifier.citedreference | Proye, C. et al. 1992. High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out of 100 patients operated from 1971 to 1991. J. Endocrinol. Invest. 15: 651 – 663. | en_US |
dc.identifier.citedreference | Tischler, A. 1998. The adrenal medulla and extra-adrenal paraganglia. In Functional Endocrine Pathology. K. Kovacs & S. Asa, Eds.: 550 – 595. Blackwell. Oxford. | en_US |
dc.identifier.citedreference | Goldstein, R.E. et al. 1999. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229: 755 – 766. | en_US |
dc.identifier.citedreference | Schulz, C. et al. 2004. Principles of catecholamine biosynthesis, metabolism and release. Front. Horm. Res. 31: 1 – 25. | en_US |
dc.identifier.citedreference | Wieland, D.M. et al. 1980. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [ 131 I]iodobenzylguanidine. J. Nucl. Med. 21: 349 – 353. | en_US |
dc.identifier.citedreference | Sisson, J.C. et al. 1981. Scintigraphic localization of pheochromocytoma. N. Engl. J. Med. 305: 12 – 17. | en_US |
dc.identifier.citedreference | Shulkin, B. et al. 1986. 123I-4-Amino-3-iodobenzylguanidine (123I-AIBG), a new sympatho-adrenal imaging agent: comparison with 123I-meta-iodobenzylguanidine (123I-MIBG). J. Nucl. Med. 27: 1138 – 1142. | en_US |
dc.identifier.citedreference | Shulkin, B.L. et al. 1992. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J. Nucl. Med. 33: 1125 – 1131. | en_US |
dc.identifier.citedreference | Trampal, C. et al. 2004. Pheochromocytomas: detection with 11 C hydroxyephedrine PET. Radiology 230: 423 – 428. | en_US |
dc.identifier.citedreference | Shulkin, B.L. et al. 1995. PET epinephrine studies of pheochromocytoma. J. Nucl. Med. 36: 22P – 23P. | en_US |
dc.identifier.citedreference | Ilias, I. et al. 2003. Superiority of 6-[ 18 F]-fluorodopamine positron emission tomography versus [ 131 I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J. Clin. Endocrinol. Metab. 88: 4083 – 4087. | en_US |
dc.identifier.citedreference | Ilias, I. et al. 2004. Comparison of 6-[ 18 F]-fluorodopamine positron emission tomography with [123In]-metaiodobenzylguanidine and [111In]-pentetreotide scintigraphy in the localization of pheochromocytoma, ENDO. 86th Annual Meeting of the American Endocrine Society, New Orleans, LA, The Endocrine Society: 452 – 453. | en_US |
dc.identifier.citedreference | Hoegerle, S. et al. 2002. Pheochromocytomas: detection with 18 F DOPA whole body PET—initial results. Radiology 222: 507 – 512. | en_US |
dc.identifier.citedreference | Shulkin, B.L. et al. 1999. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212: 35 – 41. | en_US |
dc.identifier.citedreference | Mamede, M. et al. 2005. Discordant localization of [18-F]-fluorodeoxyglucose, in [18-F]-fluorodopamine-negative metastatic pheochromocytoma sites. J. Nucl. Med. 46 ( CD-ROM Suppl. ): 1324. | en_US |
dc.identifier.citedreference | Ezuddin, S. et al. 2005. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin. Nucl. Med. 30: 579 – 581. | en_US |
dc.identifier.citedreference | Hofland, L.J. et al. 1999. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J. Clin. Endocrinol. Metab. 84: 775 – 780. | en_US |
dc.identifier.citedreference | Reubi, J.C. et al. 1992. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 74: 1082 – 1089. | en_US |
dc.identifier.citedreference | Mundschenk, J. et al. 2003. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J. Clin. Endocrinol. Metab. 88: 5150 – 5157. | en_US |
dc.identifier.citedreference | van der Harst, E. et al. 2001. [(123)I]metaiodobenzylguanidine and [(111)In ]octreotide uptake in benign and malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86: 685 – 693. | en_US |
dc.identifier.citedreference | Schmidt, M. et al. 2002. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur. J. Nucl. Med. Mol. Imaging 29: 1571 – 1580. | en_US |
dc.identifier.citedreference | Lamberts, S.W. et al. 1990. Somatostatin-receptor imaging in the localization of endocrine tumors. N. Engl. J. Med. 323: 1246 – 1249. | en_US |
dc.identifier.citedreference | Krenning, E.P. et al. 1993. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716 – 731. | en_US |
dc.identifier.citedreference | Telischi, F.F. et al. 2000. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol. Head Neck Surg. 122: 358 – 362. | en_US |
dc.identifier.citedreference | Duet, M. et al. 2003. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J. Nucl. Med. 44: 1767 – 1774. | en_US |
dc.identifier.citedreference | Bustillo, A. et al. 2004. Octreotide scintigraphy in the head and neck. Laryngoscope 114: 434 – 440. | en_US |
dc.identifier.citedreference | Berry, C.R. et al. 2002. Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. Vet. Radiol. Ultrasound. 43: 183 – 186. | en_US |
dc.identifier.citedreference | Plachcinska, A. et al. 2003. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur. J. Nucl. Med. Mol. Imaging 30: 1402 – 1406. | en_US |
dc.identifier.citedreference | Hofmann, M. et al. 2001. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28: 1751 – 1757. | en_US |
dc.identifier.citedreference | Anderson, C.J. et al. 2001. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 42: 213 – 221. | en_US |
dc.identifier.citedreference | Wester, H.J. et al. 2003. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. Mol. Imaging 30: 117 – 122. | en_US |
dc.identifier.citedreference | Schottelius, M. et al. 2004. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin. Cancer Res. 10: 3593 – 3606. | en_US |
dc.identifier.citedreference | Kowalski, J. et al. 2003. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT: first results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5: 42 – 48. | en_US |
dc.identifier.citedreference | Gabriel, M. et al. 2003. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med. 44: 708 – 716. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.